Company news
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) news
Every Aldeyra Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 3
Aldeyra Therapeutics Initiates Phase 2 Clinical Trial of ADX-2191 for the Treatment of Retinitis Pigmentosa
March 8, 2022
Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Model
February 1, 2022
Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®
January 11, 2022
Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
January 4, 2022
Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease
December 20, 2021
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance
November 9, 2021
Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double-Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease
November 2, 2021
Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights
October 28, 2021
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2021 Financial Results and Discuss Recent Business Highlights
October 21, 2021
Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights
August 5, 2021
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa
August 4, 2021
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2021 Financial Results and Discuss Recent Business Highlights
July 29, 2021
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Primary Vitreoretinal Lymphoma
July 20, 2021
Aldeyra Therapeutics Joins the Russell 2000® and Russell 3000® Indexes
July 1, 2021
Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights
May 6, 2021
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2021 Financial Results and Discuss Recent Business Highlights
April 29, 2021
Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
April 28, 2021
Aldeyra Therapeutics, Inc. Announces Proposed $125 Million Public Offering of Common Stock
April 27, 2021
Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis
April 27, 2021
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE Clinical Trial
April 26, 2021
Aldeyra Therapeutics Reports Full-Year 2020 Financial Results and Recent Business Highlights
March 11, 2021
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2020 Financial Results and Discuss Recent Business Highlights
March 4, 2021
Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Design
February 4, 2021
Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 20, 2021
Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
January 13, 2021
Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
January 13, 2021
Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease
January 7, 2021
Aldeyra Therapeutics Announces Confirmation of Antiviral Activity of ADX-1612
December 22, 2020
Aldeyra Therapeutics Announces Initiation of Phase 2 Clinical Trials of ADX-629, a First-in-Class Orally Administered RASP Inhibitor, for the Treatment of COVID-19, Atopic Asthma, and Psoriasis
December 17, 2020
Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Disease
December 8, 2020
Aldeyra Therapeutics Announces Third-Quarter 2020 Financial Results and Provides Corporate Update
November 5, 2020
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2020 Financial Results and Corporate Update
October 29, 2020
Aldeyra Receives Study May Proceed Letter from FDA to Initiate Clinical Trial of ADX-629 in COVID-19 Patients
September 9, 2020
Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update
August 6, 2020
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second-Quarter 2020 Financial Results and Corporate Update
July 30, 2020
Aldeyra Therapeutics Announces Stock Sales to Perceptive Advisors and Avidity Partners
July 14, 2020
Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease
July 7, 2020
Aldeyra Therapeutics Receives Orphan Medicinal Product Designation from the European Commission for ADX-2191 Retinal Disease Program
June 15, 2020
Aldeyra Therapeutics Reaches Agreement with the US Food and Drug Administration for the Use of RASP as an Objective Sign for the Treatment of Dry Eye Disease
June 4, 2020
Aldeyra Therapeutics to Advance ADX-1612, an Investigational New HSP90 Inhibitor with Potential Nanomolar Potency Against SARS-CoV-2, to Clinical Testing for COVID-19; ADX-629 Accepted for BARDA CoronaWatch Meeting
May 20, 2020
Aldeyra Therapeutics Reports First-Quarter 2020 Financial Results and Announces New Clinical Programs
May 7, 2020
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First-Quarter 2020 Financial Results and Corporate Update
April 30, 2020
Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629
April 14, 2020
Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection
March 24, 2020
Aldeyra Therapeutics Reports Full-Year 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones
March 12, 2020
Aldeyra Announces Strategic Prioritization of Late-Stage Clinical Pipeline in Ocular Disease
March 12, 2020
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Fourth-Quarter and Full-Year 2019 Financial Results and Corporate Update
March 5, 2020
Aldeyra Therapeutics to Host 2020 Research & Development Day
February 11, 2020
Aldeyra Therapeutics Appoints Dr. Paul Karpecki to Anterior Segment Scientific Advisory Board
January 28, 2020
Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 INVIGORATE Trial in Allergic Conjunctivitis
January 21, 2020